Smoking is a major cause of avoidable morbidity and mortality in the United States. While over 70% of smokers would like to quit smoking, fewer than 10% succeed in quitting. Recently, the SLC6A3 gene has been found to predispose smokers to nicotine dependence. A companion clinical trial (Project 2) proposed in this TTURC grant application will determine the efficacy of transdermal nicotine patches (TN) and nicotine nasal spray (NS) in smokers with protective and predisposing SLC6A3 genotypes. However, the long-term health outcomes and costs of care associated with these cessation strategies are not known. To address this important gap, the investigators will use cost-effectiveness analysis to examine costs and outcomes of three strategies for smoking cessation. 1) using counseling and TN for all smokers making a quit attempt; 2) using counseling and NS for all smokers attempting to quit; and 3) gene testing all smokers making a quit attempts, and tailoring treatment such that those with protective genotypes receive counseling and T, and those with predisposing genotypes receive counseling and NS.
The specific aims of the study are 1) to collect health preference data from participants of a randomized clinical trial of NS versus TN to test the hypothesis that successful quitters have higher health-related quality of life than those making unsuccessful quit attempts, and 2) to perform a cost-effectiveness analysis incorporating health preference data from aim (1), longevity, and costs to test the hypothesis that using SLC6A3 gene testing to tailor therapy will be cost-effective compared to treatment of all smokers with either TN or NS. The proposed study will have two components. First, health-preference data will be collected on at least 700 smokers enrolled in the clinical trial (Project 2). Second, a computer simulation model will be constructed which incorporates smokers' health preferences, clinical trial data from Project 2 on cessation rates for TN and NS stratified by gene status and medial literature data on longevity based upon smoking status. This model will calculate the long-term costs and outcomes of the three cessation strategies. Results will be presented as incremental cost- effectiveness ratios with units of cost per quality-adjusted life year saved and cost per successful quit. The proposed study represents an innovative approach to the rapid assessment of SLC6A3 gene testing. Data from this proposal will provide a framework for health policy guidelines that maximize the health of the smoking population for an acceptable cost.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA084718-03S1
Application #
6507174
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-04-01
Project End
2001-09-29
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Hsu, Ping-Ching; Lan, Renny S; Brasky, Theodore M et al. (2017) Metabolomic profiles of current cigarette smokers. Mol Carcinog 56:594-606
Hsu, Ping-Ching; Lan, Renny S; Brasky, Theodore M et al. (2017) Menthol Smokers: Metabolomic Profiling and Smoking Behavior. Cancer Epidemiol Biomarkers Prev 26:51-60
Weng, Daniel Y; Chen, Jinguo; Taslim, Cenny et al. (2016) Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Mol Carcinog 55:1424-37
Song, Min-Ae; Marian, Catalin; Brasky, Theodore M et al. (2016) Chemical and toxicological characteristics of conventional and low-TSNA moist snuff tobacco products. Toxicol Lett 245:68-77
Schnoll, Robert A; Goelz, Patricia M; Veluz-Wilkins, Anna et al. (2015) Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 175:504-11
David, Sean P; Strong, David R; Leventhal, Adam M et al. (2013) Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 108:2202-11
Bough, K J; Lerman, C; Rose, J E et al. (2013) Biomarkers for smoking cessation. Clin Pharmacol Ther 93:526-38
Perkins, Kenneth A; Parzynski, Craig; Mercincavage, Melissa et al. (2012) Is self-efficacy for smoking abstinence a cause of, or a reflection on, smoking behavior change? Exp Clin Psychopharmacol 20:56-62
Conklin, Cynthia A; Parzynski, Craig S; Salkeld, Ronald P et al. (2012) Cue reactivity as a predictor of successful abstinence initiation among adult smokers. Exp Clin Psychopharmacol 20:473-8
Featherstone, Robert E; Phillips, Jennifer M; Thieu, Tony et al. (2012) Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials. PLoS One 7:e39775

Showing the most recent 10 out of 148 publications